Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 26

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Embolism

Recruiting

Study of REGN7508 versus apixaban for treating and preventing cancer-associated blood clots in adults with solid or blood cancers

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban

Safety and Feasibility of Home Use On-Body Injection System for Subcutaneous Ocrelizumab in Adults with Multiple Sclerosis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ocrelizumab

Short stature

Recruiting

Weekly Somatrogon versus Daily Somatropin in Children with Small for Gestational Age or Idiopathic Short Stature

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Somatropin

Osteoarthritis

Recruiting

Efficacy and Safety of LTG-321 Compared with Placebo in Patients with Osteoarthritis of the Knee

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years

Bempedoic acid in drug combination for patients with coronary artery disease without prior cardiovascular events

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin

Bladder cancer

Recruiting

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin

A Phase 2a Study Evaluating the Efficacy and Safety of MK-8690 in Adults with Moderately to Severely Active Ulcerative Colitis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

Safety and Tolerability of Intrathecal TRCN-1023 in Adults with Amyotrophic Lateral Sclerosis (ALS) – Randomized Placebo‑Controlled Phase 1/2 Trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years

Long‑Term Safety Study of ADX‑324 in Participants with Hereditary Angioedema (Phase 3 Extension)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ADX-324

Epcoritamab for Adults with Relapsed or Refractory Marginal Zone Lymphoma: A Phase II Open‑Label Study

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab

Switch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate

Long‑Term Safety Follow‑up of Ornithine Transcarbamylase Deficiency Patients Treated with ECUR‑506D and ECUR‑506A

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Adeno-Associated Virus Serotype Rh79 Containing The Human Otc Gene
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.